Piramal Pharma's FY2025 Sustainability Report: A Commitment to Responsible Growth and Decarbonization

Overview

Piramal Pharma Limited (PPL), a prominent player in the global pharmaceutical sector, has recently unveiled its fourth annual Sustainability Report for the financial year 2025. This year's report adopts the theme of "Innovating Responsibly. Growing Sustainably," which reflects PPL's unwavering commitment to sustainability and ethical practices. The report offers an in-depth look at the company's measurable progress and reinforced commitments across its four strategic pillars: Business Resilience, Quality Excellence, Responsible Operations, and Stakeholder Centricity.

Key Highlights

Business Resilience

PPL's approach to governance includes ensuring that half of its board members are independent and achieving 30% representation of women, surpassing legal mandates. The company has recorded zero data breaches and has achieved full compliance with its Code of Conduct training. Additionally, it assessed 26.5% of its critical suppliers based on sustainability criteria, aiming for capacity building for 30% of these suppliers by FY2026.

Quality Excellence

PPL successfully navigated 36 regulatory inspections, including two from the US FDA, and completed 165 global customer audits. The company continues to innovate digitally, employing tools like Catalyst NxGen (S/4HANA) while enhancing operational agility through 17 governance dashboards. PPL also reported impressive customer satisfaction scores of 85% in the CDMO/PPS sector and 87% in Critical Care/PCC.

Responsible Operations

PPL outlined substantial decarbonization milestones, with a 6% reduction in Scope 1 and 2 emissions compared to the previous year. Renewable energy usage has risen by 7.8%, with bioenergy constituting 20.2% of total energy consumption. Impressively, the company sent zero hazardous waste to landfills and aims to recycle 90% of non-hazardous waste. Its integrated water stewardship saved approximately 210,000 kilolitres of freshwater.

In a noteworthy initiative, PPL transformed its coal-fired steam boiler at the Digwal facility in India to run on renewable biomass briquettes, marking a significant step in its sustainability strategies.

Stakeholder Centricity

On the diversity, equity, and inclusion (DEI) front, PPL has made commendable strides. Women now represent 30% of the board and 20% of the global workforce, which reflects a year-on-year increase of 2.7%. Additionally, 63.3% of campus hires are women, and the entire workforce is covered under ESG training. Safety initiatives led to an impressive 45% improvement in the Lost Time Injury Rate (LTIR), reducing it to 0.05.

Statement from Leadership

Nandini Piramal, Chairperson of Piramal Pharma Limited, emphasized that sustainability is not merely a corporate responsibility but a pivotal choice shaping operations and growth. In an era characterized by climate change, regulatory evolution, and the demand for ethical transparency, sustainability has emerged as essential for lasting value creation. The recent year has seen tangible reductions in emissions, expanded renewable adoption, and enhanced efforts toward water stewardship and circular practices. PPL's commitment to DEI has fostered a more inclusive corporate culture, while its CSR initiatives positively impacted over 200 million individuals across various districts.

Community Engagement and CSR Initiatives

In FY2025, PPL, in partnership with the Piramal Foundation, extended its CSR initiatives across 112 aspirational districts in India, focusing on education, health, and women's empowerment. The company invested ₹5.34 Crore in projects aimed at enhancing school infrastructure and public health outcomes. Employee volunteering initiatives further amplified PPL's community impact through plantation drives, health campaigns, and immersive community projects.

PPL also collaborated with the Life Sciences Sector Skill Development Council to establish a women-led skill development program near its Digwal plant. Continuing its support for the Aspirational Bharat Collaborative (ABC), the company remained dedicated to its mission of elevating the lives of 100 million underserved individuals by the year 2047.

Compliance and Sustainability Standards

The Sustainability Report follows GRI standards and aligns with SASSB and UNGC frameworks, reaffirming PPL's commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement.

For more insights, the full report can be accessed at Piramal Pharma Sustainability Report FY2025.

About Piramal Pharma Limited

Piramal Pharma Limited (PPL) operates a diversified portfolio through 17 global development and manufacturing facilities, serving clients in over 100 countries. Its businesses encompass Piramal Pharma Solutions (PPS), which provides integrated contract development and manufacturing services, Piramal Critical Care (PCC) focused on hospital generics, and Piramal Consumer Healthcare, catering to over-the-counter wellness products. An associate company of PPL, Abbvie Therapeutics India Private Limited, holds a strong position in the Indian ophthalmology market.

For further details, visit Piramal Pharma.